SELLAS Q2 net loss $0.07/sh; GPS Phase 3 IDMC positive; SLS009 meets endpoints

SELLAS Life Sciences Group, Inc.

2025-Q2 EPS reported -$0.13 vs consensus -$0.08 ▼ miss (-56.3%)

IDMC recommends continuing pivotal Phase 3 REGAL trial of GPS in AML without modification; final analysis by year-end 2025.
Phase 2 SLS009 in r/r AML met all primary endpoints: 44% ORR in AML-MRC; median OS 8.9 months vs 2.4 month historical benchmark.
FDA recommends advancing SLS009 into first-line AML trial; 80-patient enrollment expected by Q1 2026.
Q2 2025 net loss $6.6M ($0.07/sh) vs $7.5M ($0.13/sh) in Q2 2024.
Cash $25.3M at June 30, 2025; additional $4.0M from warrant exercises in July 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.